Vol 14 (2023): Continuous Publishing
Review paper
Published online: 2023-06-15
Endocrine-related adverse events associated with targeted treatment and immune checkpoint blockage in hematological malignancies
12
, 1, 13, 1, 1
, 1, 13, 1, 1
Hematology in Clinical Practice 2023;14:11-17.
Abstract
The introduction of tyrosine kinase inhibitors and immune checkpoint inhibitors considerably improved the treatment of many hematological malignancies. However, these new classes of drugs are associated with novel hitherto not observed endocrine-related adverse effects. Therefore, this review aims to get insight into the pathogenesis of endocrine-related AEs and summarize their management according to the current European recommendations.
Keywords: endocrine complicationstyrosine kinase inhibitorsimmunotherapyimmune checkpointsthyroiditishypophysitis
References
- Salik B, Smyth MJ, Nakamura K. Targeting immune checkpoints in hematological malignancies. J Hematol Oncol. 2020; 13(1): 111.
- Pottier C, Fresnais M, Gilon M, et al. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers (Basel). 2020; 12(3).
- de Groot JW, Zonnenberg BA, Plukker JTM, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther. 2005; 78(4): 433–438.
- Lodish MB, Stratakis CA. Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer. 2010; 17(3): R233–R244.
- Hradska K, Hajek R, Jelinek T. Toxicity of immune-checkpoint inhibitors in hematological malignancies. Front Pharmacol. 2021; 12: 733890.
- Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018; 4(12): 1721–1728.
- Litwińczuk M, Szydełko J, Szydełko M, et al. Powikłania endokrynologiczne i metaboliczne terapii chorób rozrostowych układu krwiotwórczego. Hematologia. 2020; 11(3): 113–124.
- Paschou SA, Stefanaki K, Psaltopoulou T, et al. How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open. 2021; 6(1): 100011.
- Husebye ES, Castinetti F, Criseno S, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022; 187(6): G1–G21.
- Modi D, Potugari B, Uberti J. Immunotherapy for diffuse large B-cell lymphoma: current landscape and future directions. Cancers (Basel). 2021; 13(22).
- Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010; 236(1): 219–242.
- Pinato DJ, Marron TU, Mishra-Kalyani PS, et al. Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice. Eur J Cancer. 2021; 157: 140–152.
- Paschou SA, Liontos M, Eleftherakis-Papaiakovou E, et al. Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression-free and overall survival. Front Oncol. 2022; 12: 847917.
- Iyer PC, Cabanillas ME, Waguespack SG, et al. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018; 28(10): 1243–1251.
- Bednarczuk T, Brix TH, Schima W, et al. 2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction. Eur Thyroid J. 2021; 10(4): 269–284.
- Drui D, Illouz F, Do Cao C, et al. Expert opinion on thyroid complications of new anti-cancer therapies: tyrosine kinase inhibitors. Ann Endocrinol (Paris). 2018; 79(5): 569–573.
- Bhattacharya S, Goyal A, Kaur P, et al. Anticancer drug-induced thyroid dysfunction. Eur Endocrinol. 2020; 16(1): 32–39.
- Illouz F, Braun D, Briet C, et al. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol. 2014; 171(3): R91–R99.
- González-Rodríguez E, Rodríguez-Abreu D. Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist. 2016; 21(7): 804–816.
- Kurimoto C, Inaba H, Ariyasu H, et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 2020; 111(5): 1468–1477.
- Yang S, Yu KH, Palmer N, et al. Autoimmune effects of lung cancer immunotherapy revealed by data-driven analysis on a Nationwide cohort. Clin Pharmacol Ther. 2020; 107(2): 388–396.
- Nadczynność tarczycy. http://www.mp.pl/social/chapter/B16.II.9.2 (March 20, 2023).
- Niedoczynność tarczycy. ww.mp.pl/social/chapter/B16.II.9.1 (March 20, 2023).
- Mahzari M, Liu D, Arnaout A, et al. Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes. 2015; 8: 21–28.
- Iwama S, De Remigis A, Callahan MK, et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014; 6(230): 230ra45.
- Zhao C, Tella SH, Del Rivero J, et al. Anti-PD-L1 treatment induced central diabetes insipidus. J Clin Endocrinol Metab. 2018; 103(2): 365–369.
- Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010; 13(1): 29–38.
- Hughes J, Vudattu N, Sznol M, et al. Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care. 2015; 38(4): e55–e57.
- Hattersley R, Nana M, Lansdown AJ. Endocrine complications of immunotherapies: a review. Clin Med (Lond). 2021; 21(2): e212–e222.
- Gubbi S, Hannah-Shmouni F, Verbalis JG, et al. Hypophysitis: an update on the novel forms, diagnosis and management of disorders of pituitary inflammation. Best Pract Res Clin Endocrinol Metab. 2019; 33(6): 101371.
- Yeku OO, Purdon TJ, Koneru M, et al. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. 2017; 7(1): 10541.
- Duell J, Lammers PE, Djuretic I, et al. Bispecific antibodies in the treatment of hematologic malignancies. Clin Pharmacol Ther. 2019; 106(4): 781–791.
- Chen P, Xia Y, Lei W, et al. Case report: Hashimoto's thyroiditis after CD19 chimeric antigen receptor T-cell therapy. Front Immunol. 2022; 13: 995496.
